Stock Events

Stock Events

Boundless Bio 

$2.82
1
-$0.07-2.42% Monday 20:00
+$0.10+3.55%Monday 23:39After hours

Statistics

Day High
2.83
Day Low
2.83
52W High
2.89
52W Low
1.05
Volume
2,924
Avg. Volume
-
Mkt Cap
63.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
Next
-1.06
-0.89
-0.73
-0.56
Expected EPS
-0.56
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
2025
0Revenue
-58.2MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics focuses on gene editing technologies, directly competing in the genetic medicine space similar to Boundless Bio's approach to oncology.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine works on genome editing technology, which is a direct competitor to Boundless Bio's gene-targeting therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the same gene editing sector as Boundless Bio.
Beam Therapeutics
BEAM
Mkt Cap3.36B
Beam Therapeutics uses base editing technology, a form of gene editing that competes with Boundless Bio's precision oncology solutions.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, which are part of the broader field of genetic medicine, overlapping with Boundless Bio's market.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, competing in the genetic disorder treatment market like Boundless Bio.
Fate Therapeutics
FATE
Mkt Cap361.33M
Fate Therapeutics works on programmed cellular immunotherapies, which compete with Boundless Bio's focus on innovative biotechnologies for cancer treatment.
Adaptive Biotechnologies
ADPT
Mkt Cap3.37B
Adaptive Biotechnologies focuses on the immune-driven discovery and development of treatments, competing in the personalized medicine space with Boundless Bio.

About

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Show more...
CEO
Ms. Jessica Oien J.D.
Employees
28
Country
United States
ISIN
US10170A1007

Listings

XNAS
US
BOLD
BOATS
BOATS
BOLD.BOATS

0 Comments

Share your thoughts

FAQ

What is Boundless Bio stock price today?▼
The current price of BOLD is $2.82 USD — it has decreased by -2.42% in the past 24 hours. Watch Boundless Bio stock price performance more closely on the chart.
What is Boundless Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Boundless Bio stocks are traded under the ticker BOLD.
Is Boundless Bio stock price growing?▼
BOLD stock has risen by +4.25% compared to the previous week, the month change is a +17.01% rise, over the last year Boundless Bio has showed a +154.05% increase.
What is Boundless Bio market cap?▼
Today Boundless Bio has the market capitalization of 63.38M
When is the next Boundless Bio earnings date?▼
Boundless Bio is going to release the next earnings report on November 05, 2026.
What is Boundless Bio revenue for the last year?▼
Boundless Bio revenue for the last year amounts to 0 USD.
What is Boundless Bio net income for the last year?▼
BOLD net income for the last year is -58.2M USD.
How many employees does Boundless Bio have?▼
As of August 11, 2026, the company has 28 employees.
In which sector is Boundless Bio located?▼
Boundless Bio operates in the Health & Wellness sector.
When did Boundless Bio complete a stock split?▼
Boundless Bio has not had any recent stock splits.
Where is Boundless Bio headquartered?▼
Boundless Bio is headquartered in San Diego, United States.